121 related articles for article (PubMed ID: 36239473)
41. A pilot study of first-line olaratumab, doxorubicin and ifosfamide in patients with metastatic soft tissue sarcoma.
Vornicova O; Haim N; Bar-Sela G
Cancer Chemother Pharmacol; 2019 Oct; 84(4):919-923. PubMed ID: 31410509
[TBL] [Abstract][Full Text] [Related]
42. Maintenance of pegylated liposomal doxorubicin/carboplatin in patients with advanced ovarian cancer: randomized study of an Asian Gynecologic Oncology Group.
Lai CH; Vallikad E; Lin H; Yang LY; Jung SM; Liu HE; Ou YC; Chou HH; Lin CT; Huang HJ; Huang KG; Qiu J; Hung YC; Wu TI; Chang WY; Tan KT; Lin CY; Chao A; Chang CJ
J Gynecol Oncol; 2020 Jan; 31(1):e5. PubMed ID: 31788995
[TBL] [Abstract][Full Text] [Related]
43. A phase 1b trial of selinexor, a first-in-class selective inhibitor of nuclear export (SINE), in combination with doxorubicin in patients with advanced soft tissue sarcomas (STS).
Lewin J; Malone E; Al-Ezzi E; Fasih S; Pedersen P; Accardi S; Gupta A; Abdul Razak A
Eur J Cancer; 2021 Feb; 144():360-367. PubMed ID: 33418486
[TBL] [Abstract][Full Text] [Related]
44. Phase II trial of gemcitabine in patients with pretreated advanced soft tissue sarcomas.
Späth-Schwalbe E; Genvresse I; Koschuth A; Dietzmann A; Grunewald R; Possinger K
Anticancer Drugs; 2000 Jun; 11(5):325-9. PubMed ID: 10912948
[TBL] [Abstract][Full Text] [Related]
45. The role of Ifosfamide-doxorubicin chemotherapy in histology-specific, high grade, locally advanced soft tissue sarcoma, a 14-year experience.
Goy BW; Syed S; Padmanabhan A; Burchette RJ; Helmstedter CS
Radiother Oncol; 2021 Dec; 165():174-178. PubMed ID: 34758339
[TBL] [Abstract][Full Text] [Related]
46. Pegylated liposomal doxorubicin (PLD) in daily practice-A single center experience of treatment with PLD in patients with comorbidities and older patients with metastatic breast cancer.
Wallrabenstein T; Daetwyler E; Oseledchyk A; Rochlitz C; Vetter M
Cancer Med; 2023 Jun; 12(12):13388-13396. PubMed ID: 37148541
[TBL] [Abstract][Full Text] [Related]
47. Randomised phase 2 study comparing the efficacy and safety of the oral tyrosine kinase inhibitor nintedanib with single agent ifosfamide in patients with advanced, inoperable, metastatic soft tissue sarcoma after failure of first-line chemotherapy: EORTC-1506-STBSG "ANITA".
Schöffski P; Toulmonde M; Estival A; Marquina G; Dudzisz-Śledź M; Brahmi M; Steeghs N; Karavasilis V; de Haan J; Wozniak A; Cousin S; Domènech M; Bovée JVMG; Charon-Barra C; Marreaud S; Litière S; De Meulemeester L; Olungu C; Gelderblom H
Eur J Cancer; 2021 Jul; 152():26-40. PubMed ID: 34062484
[TBL] [Abstract][Full Text] [Related]
48. First-line anthracycline-based chemotherapy for angiosarcoma and other soft tissue sarcoma subtypes: pooled analysis of eleven European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group trials.
Young RJ; Natukunda A; Litière S; Woll PJ; Wardelmann E; van der Graaf WT
Eur J Cancer; 2014 Dec; 50(18):3178-86. PubMed ID: 25459395
[TBL] [Abstract][Full Text] [Related]
49. Phase II multicenter trial of anthracycline rechallenge with pegylated liposomal doxorubicin plus cyclophosphamide for first-line therapy of metastatic breast cancer previously treated with adjuvant anthracyclines.
Trudeau ME; Clemons MJ; Provencher L; Panasci L; Yelle L; Rayson D; Latreille J; Vandenberg T; Goel R; Zibdawi L; Rahim Y; Pouliot JF
J Clin Oncol; 2009 Dec; 27(35):5906-10. PubMed ID: 19858391
[TBL] [Abstract][Full Text] [Related]
50. Adjuvant chemotherapy and postoperative radiotherapy in high-risk soft tissue sarcoma patients defined by biological risk factors-A Scandinavian Sarcoma Group study (SSG XX).
Sundby Hall K; Bruland ØS; Bjerkehagen B; Zaikova O; Engellau J; Hagberg O; Hansson L; Hagberg H; Ahlström M; Knobel H; Papworth K; Zemmler M; Goplen D; Bauer HCF; Eriksson M
Eur J Cancer; 2018 Aug; 99():78-85. PubMed ID: 29929092
[TBL] [Abstract][Full Text] [Related]
51. First-Line Aldoxorubicin vs Doxorubicin in Metastatic or Locally Advanced Unresectable Soft-Tissue Sarcoma: A Phase 2b Randomized Clinical Trial.
Chawla SP; Papai Z; Mukhametshina G; Sankhala K; Vasylyev L; Fedenko A; Khamly K; Ganjoo K; Nagarkar R; Wieland S; Levitt DJ
JAMA Oncol; 2015 Dec; 1(9):1272-80. PubMed ID: 26378637
[TBL] [Abstract][Full Text] [Related]
52. Effect of Neoadjuvant Chemotherapy Plus Regional Hyperthermia on Long-term Outcomes Among Patients With Localized High-Risk Soft Tissue Sarcoma: The EORTC 62961-ESHO 95 Randomized Clinical Trial.
Issels RD; Lindner LH; Verweij J; Wessalowski R; Reichardt P; Wust P; Ghadjar P; Hohenberger P; Angele M; Salat C; Vujaskovic Z; Daugaard S; Mella O; Mansmann U; Dürr HR; Knösel T; Abdel-Rahman S; Schmidt M; Hiddemann W; Jauch KW; Belka C; Gronchi A;
JAMA Oncol; 2018 Apr; 4(4):483-492. PubMed ID: 29450452
[TBL] [Abstract][Full Text] [Related]
53. Ifosfamide plus doxorubicin in previously untreated patients with advanced soft-tissue sarcoma.
Schütte J; Mouridsen HT; Steward W; Santoro A; van Oosterom AT; Somers R; Blackledge G; Verweij J; Dombernowsky P; Thomas D
Cancer Chemother Pharmacol; 1993; 31 Suppl 2():S204-9. PubMed ID: 8453699
[TBL] [Abstract][Full Text] [Related]
54. Treatment of advanced soft-tissue sarcomas using a combined strategy of high-dose ifosfamide, high-dose doxorubicin and salvage therapies.
Leyvraz S; Herrmann R; Guillou L; Honegger HP; Christinat A; Fey MF; Sessa C; Wernli M; Cerny T; Dietrich D; Pestalozzi B;
Br J Cancer; 2006 Nov; 95(10):1342-7. PubMed ID: 17031396
[TBL] [Abstract][Full Text] [Related]
55. Phase II evaluation of doxorubicin, ifosfamide, and dacarbazine plus amphotericin B in the treatment of metastatic soft tissue sarcomas. A pilot study.
González-Manzano R; Vieitez JM; Tangco E; Fernandez de Alava E; Herranz P; Garcia-Foncillas J
Am J Clin Oncol; 1993 Aug; 16(4):332-7. PubMed ID: 8328412
[TBL] [Abstract][Full Text] [Related]
56. Doxorubicin plus dacarbazine, doxorubicin plus ifosfamide, or doxorubicin alone as a first-line treatment for advanced leiomyosarcoma: A propensity score matching analysis from the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.
D'Ambrosio L; Touati N; Blay JY; Grignani G; Flippot R; Czarnecka AM; Piperno-Neumann S; Martin-Broto J; Sanfilippo R; Katz D; Duffaud F; Vincenzi B; Stark DP; Mazzeo F; Tuchscherer A; Chevreau C; Sherriff J; Estival A; Litière S; Sents W; Ray-Coquard I; Tolomeo F; Le Cesne A; Rutkowski P; Stacchiotti S; Kasper B; Gelderblom H; Gronchi A;
Cancer; 2020 Jun; 126(11):2637-2647. PubMed ID: 32129883
[TBL] [Abstract][Full Text] [Related]
57. Interruption versus continuation of trabectedin in patients with soft-tissue sarcoma (T-DIS): a randomised phase 2 trial.
Le Cesne A; Blay JY; Domont J; Tresch-Bruneel E; Chevreau C; Bertucci F; Delcambre C; Saada-Bouzid E; Piperno-Neumann S; Bay JO; Mir O; Ray-Coquard I; Ryckewaert T; Valentin T; Isambert N; Italiano A; Clisant S; Penel N
Lancet Oncol; 2015 Mar; 16(3):312-9. PubMed ID: 25680558
[TBL] [Abstract][Full Text] [Related]
58. Phase I/II study of docetaxel, ifosfamide, and doxorubicin in advanced, recurrent, or metastatic soft tissue sarcoma (STS).
Suppiah R; Wood L; Elson P; Budd GT
Invest New Drugs; 2006 Nov; 24(6):509-14. PubMed ID: 16791410
[TBL] [Abstract][Full Text] [Related]
59. Outcomes of Elderly Patients with Advanced Soft Tissue Sarcoma Treated with First-Line Chemotherapy: A Pooled Analysis of 12 EORTC Soft Tissue and Bone Sarcoma Group Trials.
Younger E; Litière S; Le Cesne A; Mir O; Gelderblom H; Italiano A; Marreaud S; Jones RL; Gronchi A; van der Graaf WTA
Oncologist; 2018 Oct; 23(10):1250-1259. PubMed ID: 29650688
[TBL] [Abstract][Full Text] [Related]
60. Ifosfamide combination regimens for soft-tissue sarcoma.
Stuart-Harris R; Dalley D; Bell DR; Levi J; Simes RJ; Wiltshaw E
Cancer Chemother Pharmacol; 1993; 31 Suppl 2():S185-8. PubMed ID: 8453695
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
